$599

Novartis Q4 and FY ’21 Earnings Update

Novartis hosted its Q4 ’21 earnings call (press release; slides) and provided brief updates to its CVRM business, including Entresto’s market performance and updates on Leqvio’s US and UK launches. Although not discussed in detail, management stated clinical trials for both iptacopan and pelacarsen remain on track. Additionally, management stated that the Sandoz strategic review remains in progress and Novartis will “hopefully come to a decision” in H2 ’22. Below are highlights from the call.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.